Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Among authors: luger t. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial.
Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sönnichsen N, Czech W, Kapp A, Stege H, Grewe M, Schöpf E. Krutmann J, et al. Among authors: luger ta. J Am Acad Dermatol. 1998 Apr;38(4):589-93. doi: 10.1016/s0190-9622(98)70123-9. J Am Acad Dermatol. 1998. PMID: 9555799 Clinical Trial.
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, Van Der Valk PG, Bos JD. Luger T, et al. Br J Dermatol. 2001 Apr;144(4):788-94. doi: 10.1046/j.1365-2133.2001.04134.x. Br J Dermatol. 2001. PMID: 11298538 Clinical Trial.
Consensus statement on the safety profile of topical calcineurin inhibitors.
Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Paller A, de Prost Y, Puig L, Ring J, Saurat JH, Schwarz T, Shear N, Stingl G, Taieb A, Thestrup-Pedersen K; Pediatric Advisory Committee of the Food and Drug Administration. Bieber T, et al. Among authors: luger t. Dermatology. 2005;211(2):77-8. doi: 10.1159/000086431. Dermatology. 2005. PMID: 16088148 No abstract available.
Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.
Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, Giannetti A, Hawk J, Hönigsmann H, Kemeny L, Luger T, Meurer M, Murphy G, Peserico A, Ranki A, Reunala T, Saurat J, Sterry W, van de Kerkhof P. Ring J, et al. Among authors: luger t. J Eur Acad Dermatol Venereol. 2005 Nov;19(6):663-71. doi: 10.1111/j.1468-3083.2005.01315.x. J Eur Acad Dermatol Venereol. 2005. PMID: 16268869 Review.
759 results